{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:49:35Z","timestamp":1790009375065,"version":"4.0.1"},"reference-count":168,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread immune dysregulation and the production of autoantibodies targeting nuclear, cytoplasmic, and cell surface antigens. These autoantibodies are central to disease pathogenesis, contribute to immune complex formation and organ damage, and serve as essential diagnostic and prognostic markers. Their detection supports disease classification, guides clinical decision-making, and offers insight into disease activity and therapeutic response. Traditional markers such as anti-nuclear antibodies (ANA), anti-dsDNA, and anti-Sm antibodies remain diagnostic cornerstones, but growing attention is given to anti-C1q, anti-nucleosome antibodies (ANuA), anti-ribosomal P, antiphospholipid, and anti-cytokine antibodies due to their associations with specific disease phenotypes and activity. These markers may reflect disease activity, specific organ involvement, or predict flares. The mechanisms underlying their persistence include B cell tolerance failure and long-lived plasma cell activity. The aim of this review is to summarize current knowledge on the major autoantibodies in SLE, appraise available detection methods, highlight their clinical utility and limitations and present evidence on the association between antibodies and disease phenotypes.<\/jats:p>","DOI":"10.3390\/jcm14165714","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:30:36Z","timestamp":1755016236000},"page":"5714","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-1538","authenticated-orcid":false,"given":"Eleni","family":"Pagkopoulou","sequence":"first","affiliation":[{"name":"Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-4176","authenticated-orcid":false,"given":"Charalampos","family":"Loutradis","sequence":"additional","affiliation":[{"name":"First Department of Urology, G. Gennimatas Hospital, Aristotle University of Thessaloniki, 54635 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3149-6523","authenticated-orcid":false,"given":"Maria","family":"Papaioannou","sequence":"additional","affiliation":[{"name":"First Department of Urology, G. Gennimatas Hospital, Aristotle University of Thessaloniki, 54635 Thessaloniki, Greece"},{"name":"Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Daoudaki","sequence":"additional","affiliation":[{"name":"Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-9863","authenticated-orcid":false,"given":"Maria","family":"Stangou","sequence":"additional","affiliation":[{"name":"1st Department of Nephrology, Hippokration Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000\u20132004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/art.38365","article-title":"Review: Antinucleosome antibodies: A critical reflection on their specificities and diagnostic impact","volume":"66","author":"Rekvig","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Dema, B., and Charles, N. (2016). Autoantibodies in SLE: Specificities, Isotypes and Receptors. Antibodies, 5.","DOI":"10.3390\/antib5010002"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1084\/jem.20042251","article-title":"Defective B cell tolerance checkpoints in systemic lupus erythematosus","volume":"201","author":"Yurasov","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Holers, V.M. (2025). Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases. Immunobiology, 230.","DOI":"10.1016\/j.imbio.2025.152915"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cei.12296","article-title":"Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: Critical remarks","volume":"179","author":"Rekvig","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Fenton, K., Fismen, S., Hedberg, A., Seredkina, N., Fenton, C., Mortensen, E.S., and Rekvig, O.P. (2009). Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0008474"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00296-014-3058-3","article-title":"Anti-ribosomal-P antibodies in lupus nephritis, neuropsychiatric lupus, lupus hepatitis, and Chagas\u2019 disease: Promising yet limited in clinical utility","volume":"35","author":"Abraham","year":"2015","journal-title":"Rheumatol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jacobi, A.M., Zhang, J., Mackay, M., Aranow, C., and Diamond, B. (2009). Phenotypic characterization of autoreactive B cells\u2014Checkpoints of B cell tolerance in patients with systemic lupus erythematosus. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005776"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1084\/jem.20061446","article-title":"Persistent expression of autoantibodies in SLE patients in remission","volume":"203","author":"Yurasov","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood-2004-07-2507","article-title":"Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response","volume":"105","author":"Odendahl","year":"2005","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaut.2011.02.001","article-title":"Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus","volume":"36","author":"Ullal","year":"2011","journal-title":"J. Autoimmun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.rdc.2004.04.001","article-title":"Nucleosomes in the pathogenesis of systemic lupus erythematosus","volume":"30","author":"Koutouzov","year":"2004","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1084\/jem.20101048","article-title":"Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9","volume":"207","author":"Guiducci","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1172\/JCI98219","article-title":"Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus\u2013like inflammation","volume":"128","author":"Mande","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2009.04057.x","article-title":"Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes","volume":"159","author":"Li","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100246","DOI":"10.1016\/j.jtauto.2024.100246","article-title":"Association of autoantibodies with the IFN signature and NETosis in patients with systemic lupus erythematosus","volume":"9","author":"Kaan","year":"2024","journal-title":"J. Transl. Autoimmun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar1009","article-title":"B cell abnormalities in systemic lupus erythematosus","volume":"5","author":"Grammer","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yap, D.Y.H., and Chan, T.M. (2019). B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246231"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1172\/JCI70231","article-title":"Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus","volume":"123","author":"Price","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/cei.12975","article-title":"Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore","volume":"189","author":"Howe","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrrheum.2010.60","article-title":"T cells as therapeutic targets in SLE","volume":"6","author":"Kyttaris","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/JLB.6RI0319-094R","article-title":"When the balance is broken: X-linked gene dosage from two X chromosomes and female-biased autoimmunity","volume":"106","author":"Syrett","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Balaton, B.P., Cotton, A.M., and Brown, C.J. (2015). Derivation of consensus inactivation status for X-linked genes from genome-wide studies. Biol. Sex Differ., 6.","DOI":"10.1186\/s13293-015-0053-7"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.4049\/jimmunol.177.4.2088","article-title":"TLR7 ligands induce higher IFN-\u03b1 production in females","volume":"177","author":"Frommer","year":"2006","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"eaap8855","DOI":"10.1126\/sciimmunol.aap8855","article-title":"TLR7 escapes X chromosome inactivation in immune cells","volume":"3","author":"Souyris","year":"2018","journal-title":"Sci. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.4049\/jimmunol.179.9.6352","article-title":"Demethylation of CD40LG on the inactive X in T cells from women with lupus","volume":"179","author":"Lu","year":"2007","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1084\/jem.20151724","article-title":"B cell IFN-\u03b3 receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6","volume":"213","author":"Jackson","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1172\/JCI0214873","article-title":"Estrogen alters thresholds for B cell apoptosis and activation","volume":"109","author":"Grimaldi","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: Updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Damoiseaux","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrrheum.2017.74","article-title":"Antinuclear antibody testing\u2014Misunderstood or misbegotten?","volume":"13","author":"Pisetsky","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"315179","DOI":"10.1155\/2014\/315179","article-title":"Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"2014","author":"Mahler","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0065-2776(08)60641-0","article-title":"Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology","volume":"44","author":"Tan","year":"1989","journal-title":"Adv. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ching, K.H., Burbelo, P.D., Tipton, C., Wei, C., Petri, M., Sanz, I., and Iadarola, M.J. (2012). Two major autoantibody clusters in systemic lupus erythematosus. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032001"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.coi.2012.10.004","article-title":"The pathogenesis of systemic lupus erythematosus\u2014An update","volume":"24","author":"Choi","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wang, X., and Xia, Y. (2019). Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01667"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100155","DOI":"10.1016\/j.jtauto.2022.100155","article-title":"Anti-Sm antibodies in the classification criteria of systemic lupus erythematosus","volume":"5","author":"Schreurs","year":"2022","journal-title":"J. Transl. Autoimmun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/blood-2005-07-2650","article-title":"U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7","volume":"107","author":"Savarese","year":"2006","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e167799","DOI":"10.1172\/jci.insight.167799","article-title":"Positive and negative regulation of the Fc\u03b3 receptor-stimulating activity of RNA-containing immune complexes by RNase","volume":"8","author":"Naito","year":"2023","journal-title":"JCI Insight"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.autrev.2006.07.004","article-title":"Clinical and biological aspects of anti-P-ribosomal protein autoantibodies","volume":"6","author":"Toubi","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/art.42863","article-title":"Unique Interplay Between Antinuclear Antibodies and Nuclear Molecules in the Pathogenesis of Systemic Lupus Erythematosus","volume":"76","author":"Pisetsky","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/rheumatology\/keae134","article-title":"Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients","volume":"64","author":"Elbagir","year":"2025","journal-title":"Rheumatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12026-015-8705-6","article-title":"Fundamental role of C1q in autoimmunity and inflammation","volume":"63","author":"Son","year":"2015","journal-title":"Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/rheumatology\/keh354","article-title":"Autoantibodies, lupus and the science of sabotage","volume":"43","author":"Rahman","year":"2004","journal-title":"Rheumatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJM199805073381906","article-title":"Antibodies to DNA","volume":"338","author":"Hahn","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12026-012-8345-z","article-title":"Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus","volume":"55","author":"Giles","year":"2013","journal-title":"Immunol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103535","DOI":"10.1016\/j.autrev.2024.103535","article-title":"A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence","volume":"23","author":"Bruschi","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrrheum.2015.151","article-title":"Anti-DNA antibodies\u2014Quintessential biomarkers of SLE","volume":"12","author":"Pisetsky","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2249.1991.tb05775.x","article-title":"Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases","volume":"86","author":"Blanco","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0896-8411(91)90014-4","article-title":"Shifts of anti-Sm-specific antibodies in patients with systemic lupus erythematosus: Analysis by counter-immunoelectrophoresis, immunoblotting and RNA-immunoprecipitation","volume":"4","author":"Horst","year":"1991","journal-title":"J. Autoimmun."},{"key":"ref_60","first-page":"321359","article-title":"Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects","volume":"2014","author":"Cozzani","year":"2014","journal-title":"Autoimmune Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s13075-014-0450-z","article-title":"Association of cerebrospinal fluid anti-Sm antibodies with acute confusional state in systemic lupus erythematosus","volume":"16","author":"Hirohata","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00296-022-05161-w","article-title":"The diagnostic challenge of patients with anti-U1-RNP antibodies","volume":"43","author":"Elhani","year":"2023","journal-title":"Rheumatol. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102356","DOI":"10.1016\/j.jaut.2019.102356","article-title":"Evolving story of autoantibodies in systemic lupus erythematosus","volume":"110","author":"Pisetsky","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaut.2010.06.016","article-title":"B-cell epitopes of the intracellular autoantigens Ro\/SSA and La\/SSB: Tools to study the regulation of the autoimmune response","volume":"35","author":"Routsias","year":"2010","journal-title":"J. Autoimmun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/096120339700600211","article-title":"Cutaneous diseases in adults associated with anti-Ro\/SS-A autoantibody production","volume":"6","author":"McCauliffe","year":"1997","journal-title":"Lupus"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10067-008-1043-5","article-title":"Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus","volume":"28","author":"Fukuda","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2249.2000.01195.x","article-title":"Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen","volume":"120","author":"Kurien","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2476049","DOI":"10.1080\/07853890.2025.2476049","article-title":"Neonatal lupus erythematosus: An acquired autoimmune disease to be taken seriously","volume":"57","author":"Sun","year":"2025","journal-title":"Ann. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1172\/JCI115003","article-title":"Molecular definition and sequence motifs of the 52-kD component of human SS-A\/Ro autoantigen","volume":"87","author":"Chan","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_71","first-page":"75","article-title":"The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus","volume":"3","author":"Zuily","year":"2016","journal-title":"Eur. J. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"101015","DOI":"10.1016\/j.blre.2022.101015","article-title":"Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis","volume":"58","author":"Saliba","year":"2023","journal-title":"Blood Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e069717","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: Advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11910-021-01124-z","article-title":"Neurologic Manifestations of the Antiphospholipid Syndrome\u2014An Update","volume":"21","author":"Bandeira","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/BOR.0000000000000932","article-title":"Antiphospholipid syndrome management: A 2023 update and practical algorithm-based approach","volume":"35","author":"Ambati","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Pastori, D., Menichelli, D., Cammisotto, V., and Pignatelli, P. (2021). Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.715878"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaut.2008.12.002","article-title":"Neurolupus is associated with anti-ribosomal P protein antibodies: An inception cohort study","volume":"32","author":"Briani","year":"2009","journal-title":"J. Autoimmun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102463","DOI":"10.1016\/j.autrev.2020.102463","article-title":"A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus","volume":"19","author":"Choi","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/1529-0131(200010)43:10<2307::AID-ANR19>3.0.CO;2-J","article-title":"Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus","volume":"43","author":"Bruns","year":"2000","journal-title":"Arthritis Rheumatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.autrev.2012.07.002","article-title":"Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis","volume":"12","author":"Bizzaro","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.autrev.2011.10.021","article-title":"Autoantibodies in lupus: Culprits or passive bystanders?","volume":"11","author":"Rekvig","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: An update","volume":"10","author":"Katz","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jcla.20248","article-title":"Anti-histones antibodies in systemic lupus erythematosus: Prevalence and frequency in neuropsychiatric lupus","volume":"22","author":"Sun","year":"2008","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.semnephrol.2015.08.002","article-title":"Genetics of Lupus Nephritis: Clinical Implications","volume":"35","author":"Munroe","year":"2015","journal-title":"Semin. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.autrev.2008.06.006","article-title":"Anti-C1q autoantibodies","volume":"7","author":"Kallenberg","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.autrev.2012.02.012","article-title":"The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA)","volume":"11","author":"Mahler","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_88","first-page":"e72310","article-title":"Not Just Myocarditis: Mixed Connective Tissue Disease (MCTD) and Overlap Myositis With Anti-Ku Positivity in a Young Male With Shortness of Breath","volume":"16","author":"Alsulami","year":"2024","journal-title":"Cureus"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-015-0573-x","article-title":"Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma","volume":"17","author":"Muro","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/1744666X.3.5.721","article-title":"Clinical implication of autoantibodies in patients with systemic rheumatic diseases","volume":"3","author":"Satoh","year":"2007","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: Their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/107999003321532475","article-title":"Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia","volume":"23","author":"Slavikova","year":"2003","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/ndt\/gfx220","article-title":"Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus","volume":"33","author":"Branco","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/art.39607","article-title":"Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1177\/0961203315575586","article-title":"Diagnosis and risk stratification in patients with anti-RNP autoimmunity","volume":"24","author":"Carpintero","year":"2015","journal-title":"Lupus"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12016-017-8653-0","article-title":"Neonatal Systemic Lupus Erythematosus Syndrome: A Comprehensive Review","volume":"53","author":"Vanoni","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chan, E.K.L., Damoiseaux, J., Carballo, O.G., Conrad, K., de Melo Cruvinel, W., Francescantonio, P.L.C., Fritzler, M.J., Garcia-De La Torre, I., Herold, M., and Mimori, T. (2015). Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00412"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.peptides.2015.04.012","article-title":"A short history, principles, and types of ELISA, and our laboratory experience with peptide\/protein analyses using ELISA","volume":"72","author":"Aydin","year":"2015","journal-title":"Peptides"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00580-021-03302-4","article-title":"Monoplex and multiplex immunoassays: Approval, advancements, and alternatives","volume":"31","author":"Ahsan","year":"2022","journal-title":"Comp. Clin. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.molmed.2018.02.003","article-title":"Mechanisms of Tissue Injury in Lupus Nephritis","volume":"24","author":"Rosetti","year":"2018","journal-title":"Trends Mol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0961203320932219","article-title":"Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: A pragmatic review mapping disease severity and progression","volume":"29","author":"Mahajan","year":"2020","journal-title":"Lupus"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.42941","article-title":"Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response","volume":"76","author":"Fava","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2016.09.002","article-title":"Anti-dsDNA antibodies and resident renal cells\u2014Their putative roles in pathogenesis of renal lesions in lupus nephritis","volume":"185","author":"Yung","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.20980","article-title":"Relationship between anti\u2013double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus","volume":"52","author":"Linnik","year":"2005","journal-title":"Arthritis Rheumatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-025-03536-5","article-title":"Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis","volume":"27","author":"Calatroni","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.4049\/jimmunol.0803573","article-title":"Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells","volume":"183","author":"Bigler","year":"2009","journal-title":"J. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e1279","DOI":"10.1002\/cti2.1279","article-title":"Autoantibodies against complement component C1q in systemic lupus erythematosus","volume":"10","author":"Trendelenburg","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.4049\/jimmunol.0802626","article-title":"CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis","volume":"183","author":"Steinmetz","year":"2009","journal-title":"J. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/art.33488","article-title":"Immunologic characteristics of intrarenal T cells: Trafficking of expanded CD8+ T cell \u03b2-chain clonotypes in progressive lupus nephritis","volume":"64","author":"Winchester","year":"2012","journal-title":"Arthritis Rheumatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.1400931","article-title":"IL-17 promotes murine lupus","volume":"193","author":"Amarilyo","year":"2014","journal-title":"J. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"103422","DOI":"10.1016\/j.autrev.2023.103422","article-title":"Is per-protocol kidney biopsy required in lupus nephritis?","volume":"23","author":"Parodis","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1016\/j.ekir.2022.09.012","article-title":"Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis","volume":"7","author":"Rossi","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kosa\u0142ka-W\u0119giel, J., Dziedzic, R., Siwiec-Ko\u017alik, A., Spa\u0142kowska, M., Milewski, M., Wach, A., Zar\u0119ba, L., Bazan-Socha, S., and Korkosz, M. (2024). Comparison of Clinical and Laboratory Characteristics in Lupus Nephritis vs. Non-Lupus Nephritis Patients\u2014A Comprehensive Retrospective Analysis Based on 921 Patients. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154486"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Saegusa, K., Tsuchida, Y., Komai, T., Tsuchiya, H., and Fujio, K. (2025). Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26030929"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Venturelli, V., and Isenberg, D.A. (2023). Targeted Therapy for SLE\u2014What Works, What Doesn\u2019t, What\u2019s Next. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093198"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.61.10.922","article-title":"Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)","volume":"61","author":"Arzoo","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheumatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.semarthrit.2011.06.004","article-title":"Rituximab therapy in refractory neuropsychiatric lupus: Current clinical evidence","volume":"41","author":"Estrada","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheumatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","article-title":"Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-\u03b1 receptor 1 antibody","volume":"7","author":"Peng","year":"2015","journal-title":"MAbs"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-\u03b1 Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.41598","article-title":"Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.31138\/mjr.260624.cto","article-title":"Clinical Trials of Interferon Inhibitors in Systemic Lupus Erythematosus and Preliminary Real-World Efficacy of Anifrolumab","volume":"35","author":"Fanouriakis","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.41608","article-title":"The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model","volume":"73","author":"Marinov","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","article-title":"Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab","volume":"61","author":"Arnold","year":"2022","journal-title":"Rheumatology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: A Review in Rheumatoid Arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheumatol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"The ACCESS Trial Group (2014). Treatment of lupus nephritis with abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol., 66, 3096\u20133104.","DOI":"10.1002\/art.38790"},{"key":"ref_145","unstructured":"Merrill, J.T., Shevell, D.E., Duchesne, D., Nowak, M., Kundu, S., Girgis, I.G., Hu, Y.S., Nadler, S.G., Banerjee, S., and Throup, J. (2018). An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study [abstract]. Arthritis Rheumatol., 70, Available online: https:\/\/acrabstracts.org\/abstract\/an-anti-cd28-domain-antibody-lulizumab-in-systemic-lupus-erythematosus-results-of-a-phase-ii-study\/."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/annrheumdis-2021-eular.1401","article-title":"POS0687 a randomised dose ranging, placebo-controlled, phase II study assessing the efficacy and safety of BI 655064, an antagonistic anti-CD40 antibody, in patients with lupus nephritis","volume":"80","author":"Jayne","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/rheumatology\/kei118","article-title":"Autoantibody to CD40 ligand in systemic lupus erythematosus: Association with thrombocytopenia but not thromboembolism","volume":"45","author":"Nakamura","year":"2006","journal-title":"Rheumatology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak\u2014STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: Biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"37","DOI":"10.31138\/mjr.231123.jia","article-title":"JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus","volume":"35","author":"Moysidou","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Alunno, A., Padjen, I., Fanouriakis, A., and Boumpas, D.T. (2019). Pathogenic and Therapeutic Relevance of JAK\/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent. Cells, 8.","DOI":"10.3390\/cells8080898"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The Jakinibs in systemic lupus erythematosus: Progress and prospects","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Lee, J., Park, Y., Jang, S.G., Hong, S.M., Song, Y.S., Kim, M.J., Baek, S., Park, S.H., and Kwok, S.K. (2021). Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.704526"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.autrev.2011.10.020","article-title":"Systemic lupus erythematosus one disease or many?","volume":"11","author":"Mosca","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13075-017-1442-6","article-title":"Predictive biological markers of systemic lupus erythematosus flares: A systematic literature review","volume":"19","author":"Gensous","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s40744-023-00601-w","article-title":"Targeting DORIS Remission and LLDAS in SLE: A Review","volume":"10","author":"Morand","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_161","first-page":"2239","article-title":"Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares","volume":"21","author":"Gladman","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1093\/rheumatology\/keaf107","article-title":"Treat-to-target in SLE: Is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab","volume":"64","author":"Gomez","year":"2025","journal-title":"Rheumatology"},{"key":"ref_163","first-page":"i78","article-title":"Omics studies: Their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases","volume":"56","author":"Teruel","year":"2017","journal-title":"Rheumatology"},{"key":"ref_164","first-page":"i32","article-title":"Systemic lupus erythematosus biomarkers: The challenging quest","volume":"56","author":"Arriens","year":"2017","journal-title":"Rheumatology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13075-016-1158-z","article-title":"Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE","volume":"18","author":"Wang","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jprot.2011.12.020","article-title":"Increased expression and phosphorylation of the two S100A9 isoforms in mononuclear cells from patients with systemic lupus erythematosus: A proteomic signature for circulating low-density granulocytes","volume":"75","author":"Zumaquero","year":"2012","journal-title":"J. Proteom."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrrheum.2017.43","article-title":"Immunometabolism in systemic lupus erythematosus","volume":"13","author":"Morel","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1002\/mco2.173","article-title":"Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy","volume":"3","author":"Zhang","year":"2022","journal-title":"MedComm"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5714\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:25:47Z","timestamp":1760034347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":168,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14165714"],"URL":"https:\/\/doi.org\/10.3390\/jcm14165714","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}